News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO, $RVVTF is going to ride the Bucci train into many markets. Getting the Canadian Defense folks to fund it for TBI/Nerve agent damage limitation/reversal is a perfect application (One I even suggested here months ago) and with the world at the peak of a Multi war front with terrorists and Rogue nations with no ethics or morals willing to use Bio/Chemical weapons with Impunity, there is a new priority for it for NATO.
Bucci for anti-Bio-Viral weapons use, to limit damage and save lives is also likely.. The funding they get and testing, the more data they have, and doors that open. Right now the FED is chocking the life out of funding for Bio-techs unless the Military funds it and needs it..
So this will keep the lights on and research going and opportunities for other Nasdaq stocks whose pipelines died, but have 2 times their market caps of cash on
hand to fund anything to keep their lights on.... as companies RVVTF might be able to JV other deals with....
Higher highs and higher lows.
$RVVTF
RVVTF will run out of money required to pay other bills before this study is complete. Hence, an r/s. They need to start generating revenues (and profits) to avoid an r/s. JMHO
Well doggie, Looky here, what have we? Looks like I was right again. Not only did they file for the patent I suggested ages ago right here, they now have Government funding, in the Middle of peak terrorism season...
$RVVTF News! Revive Therapeutics Enters into Agreement with Defense Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defense R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defense, to evaluate Bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1-2024.
DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. If promising, further studies will be conducted to facilitate Health Canada approval for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces.
“We are excited to work with the DRDC in evaluating Bucillamine as a potential therapeutic for nerve agent exposure and validating the novel uses and formulations of Bucillamine for public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks,” said Michael Frank, CEO of Revive.
I am sure most of us here lost some money but there is still hope. No reason to sell for peanuts when this could at least get back to my initial investment price of .26 cents. GLTA
"The DRDC will fund the research project, which is expected to begin in early Q1-2024". This is hugely significant and governments tend to have long pockets. My sense is this is a highly promising update and the markets seems to agree too so far today. Thanks for sharing, CW and hope you are well.
Let's see some official confirmation of this news and then the serious share buying should start again. Remained optimistic that Bucillamine would have other uses and not merely for Covid. Great stuff.
Penny I sold most but not all of this investment. I like most have no idea wtf Mf is trying now 
. That's why I said just waiting for news Dec, not like I'm holding my breath it will be Good. Why did they String us long real investors along for maybe 18 months like they had decent data for symptoms when they Knew or should of that the Trial was only taking the Very Basics for symptoms(or bad trial set up) and Why not at least give Biomedical_trader a chance at the data which he must of offered to do for free as you can see in his comment here and about how they should of unblinded the data and not lead us along for the year or so, and also I wonder if that is legal for a company to do that lol.
https://www.reddit.com/r/RVVTF/comments/15nh2p3/the_fat_lady_hasnt_sang_yet/jyp41su/?context=3
|
Followers
|
337
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36648
|
|
Created
|
02/23/17
|
Type
|
Free
|
| Moderators Classic Warrior | |||
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| | Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
|
| Mental Health (Depression, PTSD & Anxiety)
|
| Supplements for Brain Health & Cognitive Enhancement
|
AI
